With the strong evidence for VEGF as a prognostic parameter (Table 3) and the potential ability to follow LM patients with serial VEGF determinations (Figure 1), VEGF appears to be an interesting candidate for prospective evaluation in further clinical studies of LM. This evidence concerns the gene VEGFA and lymphangioma.